Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis asked for further drug data by NICE

Novartis asked for further drug data by NICE

26th March 2010

Novartis has been asked by the National Institute for Health and Clinical Excellence (NICE) to provide further clinical data on its cancer drug imatinib.

The healthcare firm is hoping to receive a recommendation from the regulatory body for its drug to be used as an adjuvant treatment to prevent cancer recurrence among patients who have had gastrointestinal stromal tumours removed.

It has already been recommended by NICE as a therapy for chronic myeloid leukaemia and gastrointestinal stromal tumours, but the body states that it has not received enough data to endorse the new specification.

The company has therefore been asked to supply evidence showing the drug’s beneficial impact on patients’ quality of life, as well as its cost-effectiveness.

Andrew Dillon, chief executive of NICE, added: “We hope that Novartis will be able to respond to the committee’s concerns.”

Earlier this month, the company published clinical trial data which demonstrated the effectiveness of its diabetes drug valsartan among sufferers of cardiovascular disease or impaired glucose tolerance.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.